Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07670416
PHASE3

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

Sponsor: Hoffmann-La Roche

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

Official title: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 in Adult Chinese Patients With Obesity or Overweight, With or Without Type 2 Diabetes Mellitus

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

300

Start Date

2026-06-25

Completion Date

2028-04-02

Last Updated

2026-06-26

Healthy Volunteers

No

Interventions

COMBINATION_PRODUCT

Enicepatide

Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.

COMBINATION_PRODUCT

Placebo

Participants will receive matching placebo via SC injection as per the schedule in the protocol.

Locations (3)

The First Affiliated Hospital of Ningbo University(Ningbo First Hospital)

Ningbo, Zhejiang, China

Peking University People's Hospital

Beijing, China

Shanghai Fifth People's Hospital Affiliated to Fudan University

Shanghai, China